Especially, Smerdou and group have demonstrated that rSFV-particles expressing IL-12 or a combination of XCL1 and Flt3L can induce strong T cell-dependent anticancer activity in murine tumor models, which could be further enhanced by immune-checkpoint blockade.12 Here, XCL1 is linked to neoplasm.